Grace Therapeutics (GRCE) EBITDA Margin (2012 - 2026)
Grace Therapeutics' EBITDA Margin came in at -11287.23% for fiscal Q1 2027 (quarter ended Jun 30, 2026), down 9773.51 percentage points from -1513.73% a year earlier and down 9107.52 percentage points from the prior quarter.
Grace Therapeutics (GRCE) EBITDA Margin (2012 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Grace Therapeutics reported EBITDA Margin of -3835.96%, down 1712.57 percentage points year-over-year; for FY2026 (ended Mar 31, 2026), it was -1616.06%, up 674.05 percentage points from FY2025.
- EBITDA Margin carries a five-year change of +6289.55 percentage points (FY2021 to FY2026).
- Going back by fiscal year, EBITDA Margin was -2290.11% in FY2025 (-822.57 pp) and -1467.54% in FY2024.
- The fiscal Q1 2027 figure represents the lowest quarterly EBITDA Margin since fiscal Q3 2016.
- Year-over-year, EBITDA Margin increased in three of the last five quarters, with an average year-over-year change of -1390.17 percentage points.
- Business Quant data shows GRCE's EBITDA Margin at -2179.71% (Q4 2026), -1422.09% (Q3 2026) and -1470.35% (Q2 2026) in the three fiscal quarters before Q1 2027.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,276.89 Bn | 1,250.50 Bn | 20.46 Bn | 36.69% |
| 2 | Johnson & Johnson | 681.31 Bn | 601.18 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 520.63 Bn | 488.64 Bn | 13.12 Bn | 46.88% |
| 4 | Merck | 357.22 Bn | 320.16 Bn | 13.19 Bn | 40.60% |
| 5 | Novartis Ag | 310.90 Bn | 284.14 Bn | - | - |
| 6 | Astrazeneca | 285.12 Bn | 258.77 Bn | 13.26 Bn | 39.77% |
| 7 | Amgen | 250.23 Bn | 201.89 Bn | 7.58 Bn | 46.62% |
| 8 | Gilead Sciences | 207.56 Bn | 182.67 Bn | 6.73 Bn | 50.63% |
| 9 | Pfizer | 164.42 Bn | 111.77 Bn | 12.56 Bn | 42.49% |
| 10 | Grace Therapeutics | 35.10 Mn | -35.61 Mn | - | -1,487.66% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -11,287.23% |
| Mar 31, 2026 | -2,179.71% |
| Dec 31, 2025 | -1,422.09% |
| Sep 30, 2025 | -1,470.35% |
| Jun 30, 2025 | -1,513.73% |
| Mar 31, 2025 | -1,728.80% |
| Dec 31, 2024 | -2,914.96% |
| Sep 30, 2024 | -2,653.30% |
| Jun 30, 2024 | -2,111.49% |
| Mar 31, 2021 | -1,999.13% |
| Dec 31, 2020 | -2,424.69% |
| Mar 31, 2018 | 83.95% |
| Nov 30, 2016 | -66.92% |
| Aug 31, 2016 | -31,524.52% |
| May 31, 2016 | -58,067.87% |
| Nov 30, 2015 | -27,333.84% |
| Aug 31, 2015 | -22,366.64% |
| May 31, 2015 | -39,216.84% |
| Feb 28, 2015 | -616.11% |
| Nov 30, 2014 | -8,261.81% |
Grace Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=GRCE&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "GRCE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=GRCE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();